View source for Gamma Knife Radiosurgery

{{TreatmentInfo
|drug_name=Gamma Knife Radiosurgery (GKRS) for GBM
|FDA_approval=Yes
|used_for=Newly diagnosed Glioblastoma Multiforme (GBM)
|clinical_trial_phase=N/A (Established treatment modality)
|common_side_effects=Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies.
|OS_without=14-16 months with standard treatment.
|OS_with=Comparable to standard treatment, specifics depend on individual patient factors.
|PFS_without=Typically, tumors recur within 6 months of standard treatment.
|PFS_with=5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.
|usefulness_rating=3
|usefulness_explanation=The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates.
|toxicity_level=2
|toxicity_explanation=GKRS, especially when utilized in a fractionated approach with the Gamma Knife ICON, presents a viable treatment option for GBM patients, emphasizing reduced side effects while maintaining efficacy.
|book_text=Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.
|links=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10162-w
}}